A novel polyester-drug nanoconjugate with subtype selectivity for high efficacy against PSMA-positive prostate cancer.

Prostate-specific membrane antigen (PSMA) positive prostate cancer (PCa) accounts for 80-90% cases. Docetaxel (DTX) is a first-line chemotherapy drug for metastatic castration resistant prostate cancer (mCRPC) and has exhibited promising efficacy. However, DTX usually causes severe side effects. To address this issue, we utilized short-chain poly(ethylene glycol) (PEG) as a monomer to prepare a water-soluble polyester, which was further modified by a PSMA ligand, 2-[3-[5-amino-1-carboxypentyl]-ureido]-pentanedioic acid (DCL) and covalently linked to DTX via a disulfide bond, resulting in a novel PSMA-targeting polyester-drug conjugate (PET-DCL-DTX). Here, the introduction of short-chain PEG into the polyester skeleton could enhance its hydrophilicity and drug-loading capacity. This conjugate is amphiphilic and forms a nanostructure via self-assembly in aqueous solution, allowing it to passively accumulate in tumor tissues via the enhanced permeability and retention (EPR) effect. Particularly, due to the specific recognition of DCL for PSMA, this nanoconjugate exerts a profound inhibitory effect on PSMA-positive PCa cells. After efficiently entering the cells, this nanoconjugate undergoes sensitive cleavage of the disulfide bond owing to the reductive molecules such as glutathione and releases DTX to suppress the PSMA-positive PCa development. Moreover, an improved safety of this nanoconjugate was observed in vivo compared to DTX alone.